Shanghai Haoyuan Chemexpress Co. Ltd. (688131.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 95.13

From 52W high−8.72%

Volume5.74M

Market capCNY 19.55B

P/E (TTM)81.5x

P/S (TTM)7.0x

Div yield0.23%

Key dataSep 18, 2026

Open

CNY 95.13

From 52W high

−8.72%

Volume

5.74M

Market cap

CNY 19.55B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

46.4x

P/E (TTM)

81.5x

RSI (14)

60.6

MomentumView details →

1D Return

−5.88%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

81.5x

EV/EBITDA

46.4x

EV/Sales

7.0x

P/S (TTM)

7.0x

P/B (TTM)

6.3x

ProfitabilityView details →

Gross Margin

48.10%

Net Margin

8.18%

EBITDA Margin

15.11%

ROE (TTM)

7.64%

ROA (TTM)

3.78%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

+26.48%

EPS YoY

−1.21%

FCF YoY

+343.64%

Revenue CAGR 3Y

+28.43%

EPS CAGR 3Y

−5.29%

EBITDA YoY

—

MomentumView details →

1D Return

−5.88%

YTD Return

—

1Y Return

—

RSI (14)

60.6

vs 50D SMA

+12.30%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.45x

Current Ratio

2.16x

Quick Ratio

1.34x

Div Yield

0.23%

Div Rate

CNY 0.23

Div Growth 1Y

+56.31%

EarningsView details →

EPS (Actual)

CNY 0.47

EPS Surprise

−1.06%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

−1.06%

Rev Surprise

−1.06%

Financials snapshotView financials →

Revenue (TTM)

3.00B

Net Income (TTM)

245.26M

Op. CF (TTM)

386.82M

Next earningsOct 29, 2026 →

Latest newsMore news →

Shanghai Chenxiao, Shanghai Chenmai and Shanghai Chenxi, pre-IPO employee shareholding platforms of Haoyuan Pharma, plan to reduce their combined stake in the company by no more than 2.34% via centralized bidding between September 17 and December 16, 2026.9d ago

Haoyuan Pharmaceutical proposed a cash dividend of 0.90 yuan per 10 shares for the first half of 2026, totaling 19.1911 million yuan, representing 11.21% of net profit attributable to shareholders.25d ago

Similar companies

Viatris Inc.VTRS HUTCHMED (China) Limited00013.HK 哈药股份600664.SH Livzon Pharmaceutical Group Inc.01513.HK Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited00874.HK Aprogen Biologics Inc.003060.KS Find similar companies →

Latest newsMore news →

Shanghai Chenxiao, Shanghai Chenmai and Shanghai Chenxi, pre-IPO employee shareholding platforms of Haoyuan Pharma, plan to reduce their combined stake in the company by no more than 2.34% via centralized bidding between September 17 and December 16, 2026.9d ago Haoyuan Pharmaceutical proposed a cash dividend of 0.90 yuan per 10 shares for the first half of 2026, totaling 19.1911 million yuan, representing 11.21% of net profit attributable to shareholders.25d ago